Precision BioSciences (NASDAQ:DTIL) Receives “Buy” Rating from HC Wainwright

Precision BioSciences (NASDAQ:DTIL)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $60.00 price target on the stock.

Separately, BMO Capital Markets upgraded Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target on the stock in a research report on Friday, January 10th.

Precision BioSciences Price Performance

Precision BioSciences stock opened at $4.54 on Friday. The stock has a 50-day moving average price of $5.12 and a two-hundred day moving average price of $6.59. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. Precision BioSciences has a 12 month low of $3.61 and a 12 month high of $15.97. The company has a market capitalization of $34.83 million, a PE ratio of 75.68 and a beta of 1.59.

Precision BioSciences (NASDAQ:DTIL) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($3.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.09) by ($1.11). Precision BioSciences had a net margin of 11.48% and a negative return on equity of 23.69%. The business had revenue of $3.47 million for the quarter, compared to the consensus estimate of $4.28 million. Analysts expect that Precision BioSciences will post -1.23 EPS for the current year.

Insider Buying and Selling at Precision BioSciences

In other news, CEO Michael Amoroso sold 36,838 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total transaction of $172,033.46. Following the transaction, the chief executive officer now owns 107,087 shares of the company’s stock, valued at $500,096.29. This represents a 25.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider J. Jefferson Smith sold 10,287 shares of the firm’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $4.79, for a total value of $49,274.73. Following the completion of the sale, the insider now directly owns 87,440 shares of the company’s stock, valued at $418,837.60. This trade represents a 10.53 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,243 shares of company stock valued at $227,424. 4.00% of the stock is currently owned by insiders.

Institutional Trading of Precision BioSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Lynx1 Capital Management LP acquired a new position in Precision BioSciences during the 4th quarter valued at about $2,919,000. Janus Henderson Group PLC grew its holdings in Precision BioSciences by 10.9% during the third quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock worth $6,322,000 after buying an additional 68,943 shares in the last quarter. Citadel Advisors LLC raised its position in Precision BioSciences by 58.0% in the 4th quarter. Citadel Advisors LLC now owns 153,675 shares of the company’s stock valued at $586,000 after buying an additional 56,400 shares during the last quarter. Moloney Securities Asset Management LLC lifted its stake in Precision BioSciences by 177.0% during the 4th quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company’s stock valued at $335,000 after acquiring an additional 56,100 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in Precision BioSciences during the 4th quarter valued at $211,000. Institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.